{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:24Z","timestamp":1793018124051,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01905-9","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:23:21Z","timestamp":1790069001000},"page":"5545-5553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a Conceptual Disease Model of Atopic Dermatitis Using Data from the Phase 3 ARCADIA 1 Trial"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-6999","authenticated-orcid":false,"given":"Danielle","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mulnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0060-9540","authenticated-orcid":false,"given":"Ramkumar","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2897-6895","authenticated-orcid":false,"given":"Liliana","family":"Ulianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-2478","authenticated-orcid":false,"given":"Christophe","family":"Piketty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Rout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-1252","authenticated-orcid":false,"given":"Jorge","family":"Puelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1905_CR1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s13555-017-0192-3","volume":"7","author":"C Jeon","year":"2017","unstructured":"Jeon C, Yan D, Nakamura M, et al. Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review. Dermatol Ther. 2017;7:349\u201364.","journal-title":"Dermatol Ther"},{"key":"1905_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clindermatol.2017.03.008","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI. Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders. Clin Dermatol. 2017;35:360\u20136.","journal-title":"Clin Dermatol"},{"key":"1905_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.anai.2017.09.076","volume":"119","author":"PP Vakharia","year":"2017","unstructured":"Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119:548-52 e3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1905_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1905_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/DER.0000000000000486","volume":"30","author":"L Grant","year":"2019","unstructured":"Grant L, Seiding Larsen L, Trennery C, et al. Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents. Dermatitis. 2019;30:247\u201354.","journal-title":"Dermatitis"},{"key":"1905_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.262","volume":"3","author":"L Cesnakova","year":"2023","unstructured":"Cesnakova L, Meadows K, Avey S, et al. A patient-centred conceptual model of nocturnal scratch and its impact in atopic dermatitis: a mixed-methods study supporting the development of novel digital measurements. Skin Health Dis. 2023;3:e262.","journal-title":"Skin Health Dis"},{"key":"1905_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40257-018-0381-6","volume":"19","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Kantor RW, Dalal P, et al. A comprehensive conceptual model of the experience of chronic itch in adults. Am J Clin Dermatol. 2018;19:759\u201369.","journal-title":"Am J Clin Dermatol"},{"key":"1905_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Reich A, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024;404:445\u201360.","journal-title":"Lancet"},{"key":"1905_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11\u20138.","journal-title":"Exp Dermatol"},{"key":"1905_CR10","unstructured":"Severity scoring of atopic dermatitis: the SCORAD index. consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993; 186:23\u201331."},{"key":"1905_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181:761\u20139.","journal-title":"Br J Dermatol"},{"key":"1905_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1398-9995.2005.00977.x","volume":"61","author":"R Kaufmann","year":"2006","unstructured":"Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy. 2006;61:375\u201381.","journal-title":"Allergy"},{"key":"1905_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s41687-020-00265-y","volume":"4","author":"C Dias-Barbosa","year":"2020","unstructured":"Dias-Barbosa C, Matos R, Vernon M, Carney CE, Krystal A, Puelles J. Content validity of a sleep numerical rating scale and a sleep diary in adults and adolescents with moderate-to-severe atopic dermatitis. J Patient Rep Outcomes. 2020;4:100.","journal-title":"J Patient Rep Outcomes"},{"key":"1905_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bjd.20783","volume":"186","author":"J Puelles","year":"2022","unstructured":"Puelles J, Fofana F, Rodriguez D, et al. Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis. Br J Dermatol. 2022;186:285\u201394.","journal-title":"Br J Dermatol"},{"key":"1905_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1905_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","volume":"145","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145:173\u201382.","journal-title":"J Allergy Clin Immunol"},{"key":"1905_CR17","doi-asserted-by":"publisher","first-page":"2417966","DOI":"10.1080\/09546634.2024.2417966","volume":"35","author":"N Durno","year":"2024","unstructured":"Durno N, Arija P, Pantiri K, et al. Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany. J Dermatolog Treat. 2024;35:2417966.","journal-title":"J Dermatolog Treat"},{"key":"1905_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamadermatol.2025.5449","volume":"162","author":"E Edwards","year":"2026","unstructured":"Edwards E, Jackson-Cowan L, Khalil N, Yap QV, Yosipovitch G. Sleep disturbance as a mediator between itch and quality of life. JAMA Dermatol. 2026;162:316\u20138.","journal-title":"JAMA Dermatol"},{"key":"1905_CR19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jaad.2024.05.100","volume":"91","author":"JF Merola","year":"2024","unstructured":"Merola JF, Chiou AS, During E, et al. Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study. J Am Acad Dermatol. 2024;91:1199\u2013201.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01905-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:06:25Z","timestamp":1793016385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01905-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1905"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01905-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jonathan I. Silverberg has received grants as a consultant and\/or advisory board member for AbbVie, Alamar, Aldena, Amgen, AOBiome, Arcutis, Arena, Asana, Aslan, BiomX, Biosion, Bodewell, Boehringer\u00a0Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, DermTech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, and Union\u00a0Therapeutics; and as a speaker for AbbVie, Eli Lilly, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme. His institution has received grants from Galderma, Incyte, and Pfizer. Patrick Daniele, Danielle Rodriguez, and Sarah Mulnick are employees of PPD Evidera Patient Centered Research, Thermo Fisher Scientific, which was paid by Galderma for work on this study. Danielle Rodriguez owns stock options in Thermo Fisher Scientific. Gil Yosipovitch has received grants and personal fees from AbbVie, Amgen, Attovia, Celldex, Galderma, Incyte, Novartis, Pfizer, Sanofi, and Sanofi Regeneron. He has also received personal fees from Arcutis, Boehringer Ingelheim, Eli Lilly, Kiniksa, LEO\u00a0Pharma, SK, and Vifor. He is the founder of the International Forum of Itch and a member of the National Psoriasis Foundation Scientific Board, National Itch Foundation Board, and International Eczema Council. Gil Yosipovitch is an Editorial Board member of Dermatology and Therapy. Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Lawrence F. Eichenfield has served as a consultant, advisor, or investigator for AbbVie, Abeona, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, Chiesi, CorEvitas, Dermavant, Eli Lilly,\u00a0Formation Bio, Forte, Galderma, Incyte, Janssen, Kenvue, Kymera, Krystal, LEO\u00a0Pharma, Novartis, OrthoDerm, Pfizer, Regeneron, Sanofi Genzyme, Takeda, Target RWE, T-Rex, UCB, and Verrica. Melinda Gooderham has been an investigator, speaker or advisory board member for AbbVie, Acelyrin, Alumis, AMGEN, AnaptysBio, Apogee Therapeutics, Arcutis, Aristea Therapeutics, Attovia, Bausch Health, Boehringer Ingelheim, Bristol\u00a0Myers Squibb, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Insmed, JAMP Pharma, Janssen, LEO Pharma, L\u2019Oreal, Meiji Seika, Merck, MoonLake Immunotherapeutics, Novartis, Oruka Therapeutics, Pfizer, Q32 Bio, Regeneron, Reistone Biopharma, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, UCB, Union Therapeutics, Ventyx, and Vyne Therapeutics.\u00a0Richard Warren has received research support from the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308). Richard Warren is an Editor-in-Chief of\n                      Dermatology and Therapy\n                      . Richard Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Ramkumar Subramanian, Katrin Jack, Liliana Ulianov, Christophe Piketty, Rajesh Rout, and Jorge Puelles are employees and stockholders of Galderma, which sponsored this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained for the ARCADIA 1 trial, which was conducted in accordance with the Declaration of Helsinki. Ethical approval was not required for the present analysis of COA data from ARCADIA 1, including the modified Delphi process.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}